Acute Myeloid Leukemia.

  title={Acute Myeloid Leukemia.},
  author={Hartmut D{\"o}hner and Daniel J. Weisdorf and Clara Derber Bloomfield},
  journal={The New England journal of medicine},
  volume={373 12},
AML is an aggressive cancer of the blood and bone marrow.1 AML prevents white blood cells from maturing, causing an accumulation of immature “blasts” (leukemic cells) which do not allow room for normal, healthy cells to grow.1 These leukemic cells can spread outside of the bloodstream and into other areas of the body, such as the central nervous system, skin and gums.1 As the leukemia spreads, infection, anemia or easy bleeding may occur due to a diminished number of healthy blood cells.1 In… 

Figures and Tables from this paper

Acute Leukemias in Adults

Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment

The bone marrow niche represents a unique microenvironment that is poised to maintain hematopoietic stem cell quiescence and hosts various mature lymphoid cell types, including naive T cells, memory T cell, and plasma cells, as well as mature myeloid elements such as monocytes and neutrophils, all of which are crucially important to control leukemia initiation and progression.

Acute myeloid leukemia-Section 1 Clinical value of new drugs in acute myeloid leukemia

The initial treatment goal is the achievement of complete remission (CR) defined already for over 40 years by morphology, and ideally this should be CR without measurable residual disease (MRD) as it is now defined in the ELN 2017 recommendation.

Acute Myeloid Leukemia Complicated by Hyperleukocytosis and Leukostasis in the Emergency Department

A case of a 65-year-old female with newly diagnosed AML complicated by leukostasis is presented, reviewing the clinical significance as well as initial diagnostic and therapeutic considerations pertaining to hyperleukocytosis and its associated complications.

Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look

The constitution of the AML niche in the bone marrow is discussed, the improvement in visualization of the complex three-dimensional niche structures is pointed out and new therapeutic strategies to increase the overall survival of AML patients are pointed out.

Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome

The spectrum of genetic aberrations detected in DCL cases in the literature is described with regard to the character of the individual cases, existing family cohorts that carry individual genes, and functional studies that support etiologic roles in AML development.

Cellular and Molecular State of Myeloid Leukemia Stem Cells.

The biological features including cellular and molecular state, heterogeneity of LSCs, and the dynamic cross talk between L SCs and bone marrow microenvironment are described to highlight the dynamic cellular state ofLSCs.

The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression.

  • B. Cardoso
  • Biology
    Advances in experimental medicine and biology
  • 2020
The bone marrow microenvironment and its key importance for leukemia expansion are described and the several components of the bone marrow niche, their interaction with the leukemic cells and the cellular pathways activated within the malignant cells will be emphasized.

Identification and characterization of candidate therapeutic targets in acute myeloid leukemia

This thesis investigated differential expression patterns of cell surface proteins on AML cells and their responsiveness to external signals as a strategy to identify novel AML dependencies, which translates into new therapeutic oppertunities.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

It is shown that CD123 is a good target for AML-directed CAR therapy, because its expression increases over time in vivo even in initially CD123(dim) populations, and that human CD123-redirected T cells (CART123) eradicate primary AML in immunodeficient mice.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

The identification of patterns of mutation acquisition in human AML supports a model in which mutations in “landscaping” genes, involved in global chromatin changes such as DNA methylation, histone modification, and chromatin looping, occur early in the evolution of AML, whereas mutations in "proliferative" genes occur late.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Analysis of serial samples from individual patients revealed that the presence of a mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was >95% specific for the diagnosis of s-AML and highlights a subset of patients with worse clinical outcomes, including a lower complete remission rate, more frequent reinduction, and decreased event-free survival.

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.

The development and evaluation of the first CARs specific for human FRβ (m909) in vitro and in vivo are described, indicating that FRβ is a promising target for CAR T-cell therapy of AML, which may be augmented by combination with ATRA.

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Genetic findings in AML are reviewed to discuss their clinical implications and identify genome-wide expression signatures that separate cytogenetic and molecular subsets of patients with AML into previously unrecognized biologic and/or prognostic subgroups.

Inherited predisposition to acute myeloid leukemia.

  • L. Godley
  • Medicine, Biology
    Seminars in hematology
  • 2014
Testing for familial predisposition to myeloid malignancies is becoming more common with the recognition of multiple familial syndromes, and new predisposition alleles are likely to be identified.

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.

In this review, the positioning of HCT in the management of patients with AML is evaluated in view of changing risk/benefit ratios associated with both conventional treatments and transplantation, and some of the controversies are addressed in light of emerging data.

Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

The authors hypothesized that low‐dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination.

How I treat refractory and early relapsed acute myeloid leukemia.

Novel therapies include tyrosine kinase inhibitors, small-molecule inhibitors, inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody- based therapies, and cell-based therapies, likely to enter clinical practice rapidly as a bridge to transplant and/or in older, unfit patients who are not candidates for allogeneic HSCT.

Antibody therapy for acute myeloid leukaemia

A number of recent trials suggest that, particularly in AML with favourable cytogenetics, GO may improve overall survival, and the development of alternative novel monoclonal antibodies (mAb) have renewed interest in the area, highlighting the potential efficacy of engineered antibodies in the treatment of acute leukaemia.